Ally Therapeutics (United States)

Recent papers from Ally Therapeutics (United States)

1. The association between undetected heteroresistance and antibiotic treatment failure in complicated urinary tract infection2025
2. Hybrid Cooperative Control of Functional Electrical Stimulation and Robot Assistance for Upper Extremity RehabilitationIEEE Transactions on Biomedical Engineering · 2024
3. Use of a mixed‐methods approach to develop a guidebook with messaging to encourage colorectal cancer screening among Black individuals 45 and olderCancer Medicine · 2023
4. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1QScience Translational Medicine · 2022
5. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responsesScience Translational Medicine · 2021
6. A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders · 2013
7. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancersCancer Chemotherapy and Pharmacology · 2009
8. Original article: The economic costs of severe anaphylaxis in France: an inquiry carried out by the Allergy Vigilance NetworkAllergy · 2008
9. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastasesBritish Journal of Cancer · 2006
10. RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary BypassCirculation · 1999